<DOC>
	<DOCNO>NCT00003578</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . It yet know whether high dose chemotherapy plus bone marrow transplantation effective high dose chemotherapy alone intermediate- high-grade non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness high dose chemotherapy without bone marrow transplantation treat patient intermediate- high-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>High Dose Chemotherapy With Without Bone Marrow Transplantation Treating Patients With Intermediate- High-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I. Assess value early intensification autologous bone marrow transplantation stem cell support patient poor prognosis intermediate high grade non-Hodgkin 's lymphoma . OUTLINE : This randomize , multicenter study . Patients stratified age ( 50 vs 50 ) , bone marrow involvement ( yes v ) , country . All patient receive cyclophosphamide , doxorubicin , vincristine day 1 prednisone day 1-5 . Courses repeat every 21 day . Patients receive minimum 6 course treatment absence disease progression unacceptable toxicity . Arm I : Patients receive carmustine IV 2 hour day 1 week 9 10 . Etoposide cytarabine IV administer 30 minute day 2-5 . Melphalan IV administer 5 minute day 6 . Patients receive cryopreserved bone marrow peripheral blood stem cell day 7 . Arm II : Patients continue conventional therapy . Patients follow 8-9 week 6 month . PROJECTED ACCRUAL : This study accrue 500 patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate high grade adult nonHodgkin 's lymphoma : Follicular large cell lymphoma Diffuse mix cell lymphoma Diffuse large cell lymphoma Diffuse immunoblastic lymphoma Poor prognostic feature define presence 2 3 following : Stage III/IV Lactase dehydrogenase great normal ECOG performance status 24 A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 16 65 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : Not specify Hepatic : See Disease Characteristics Renal : Not specify Other : No medical condition prohibit intensive therapy PRIOR CONCURRENT THERAPY : At least 5 year since prior systemic therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
</DOC>